Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions
Clinical trial NCT07410143 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07410143
- Sponsor
- EveryONE Medicines Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-13
- Primary completion
- 2026-09-30
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.